Literatura académica sobre el tema "Distal cholangiocarcinoma"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Distal cholangiocarcinoma".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Distal cholangiocarcinoma"
Dickson, Paxton V. y Stephen W. Behrman. "Distal Cholangiocarcinoma". Surgical Clinics of North America 94, n.º 2 (abril de 2014): 325–42. http://dx.doi.org/10.1016/j.suc.2013.12.004.
Texto completoLad, Neha y David A. Kooby. "Distal Cholangiocarcinoma". Surgical Oncology Clinics of North America 23, n.º 2 (abril de 2014): 265–87. http://dx.doi.org/10.1016/j.soc.2013.11.001.
Texto completoLiu, Katherine. "Distal cholangiocarcinoma". Journal of Surgical Oncology 95, n.º 3 (2007): 192–93. http://dx.doi.org/10.1002/jso.20666.
Texto completoSerafini, Francesco M., Donald Sachs, Mark Bloomston, Larry C. Carey, Richard C. Karl, Michael M. Murr y Alexander S. Rosemurgy. "Location, not Staging, of Cholangiocarcinoma Determines the Role for Adjuvant Chemoradiation Therapy". American Surgeon 67, n.º 9 (septiembre de 2001): 839–44. http://dx.doi.org/10.1177/000313480106700905.
Texto completoSallinen, V., J. Sirén, H. Mäkisalo, T. E. Lehtimäki, E. Lantto, A. Kokkola y A. Nordin. "Differences in Prognostic Factors and Recurrence Patterns After Curative-Intent Resection of Perihilar and Distal Cholangiocarcinomas". Scandinavian Journal of Surgery 109, n.º 3 (21 de febrero de 2019): 219–27. http://dx.doi.org/10.1177/1457496919832150.
Texto completoXu, Yi. "Treatment of distal cholangiocarcinoma". World Chinese Journal of Digestology 22, n.º 28 (2014): 4263. http://dx.doi.org/10.11569/wcjd.v22.i28.4263.
Texto completoPandey, Arun, Rajesh Mandal y Paleswan Joshi Lakhey. "Rare Anomaly of Common Bile Duct in Association with Distal Cholangiocarcinoma". Case Reports in Surgery 2018 (17 de diciembre de 2018): 1–3. http://dx.doi.org/10.1155/2018/8351913.
Texto completoGorji, Leva y Eliza W. Beal. "Surgical Treatment of Distal Cholangiocarcinoma". Current Oncology 29, n.º 9 (17 de septiembre de 2022): 6674–87. http://dx.doi.org/10.3390/curroncol29090524.
Texto completoKaranjia, Homyar, John A. Abraham, Brian O’Hara, Brandon Shallop, Joseph Daniel, Nicholas Taweel y Faith A. Schick. "Distal Fibula Metastasis of Cholangiocarcinoma". Journal of Foot and Ankle Surgery 52, n.º 5 (septiembre de 2013): 659–62. http://dx.doi.org/10.1053/j.jfas.2013.02.017.
Texto completoRizzo, Alessandro y Giovanni Brandi. "Novel Targeted Therapies for Advanced Cholangiocarcinoma". Medicina 57, n.º 3 (26 de febrero de 2021): 212. http://dx.doi.org/10.3390/medicina57030212.
Texto completoTesis sobre el tema "Distal cholangiocarcinoma"
Oliveira, Miguel Couto Fernandes de. "Fatores de Prognóstico no Colangiocarcinoma Distal Submetido a Duodenopancreatectomia Cefálica". Master's thesis, 2021. http://hdl.handle.net/10316/98398.
Texto completoIntrodução: O colangiocarcinoma distal (CCD) é um dos três grandes subtipos de colangiocarcinoma. Trata-se de uma neoplasia com um prognóstico muito reservado, mesmo após resseção curativa. Além disto, pela sua raridade, permanece consideravelmente mal caracterizado. Pretendeu-se caracterizar e avaliar o impacto prognóstico de marcadores clínicos, anatomopatológicos e imuno-histoquímicos em doentes com diagnóstico de CCD submetidos a resseção curativa. Materiais e Métodos: Estudo de coorte retrospetivo, com base numa amostra de 37 doentes com diagnóstico histológico de CCD, submetidos a duodenopancreatectomia cefálica entre 2008 e 2019. Verificou-se uma idade média de 69,19 (±9,92) anos, sendo 62,2% dos doentes do sexo masculino. Além da avaliação clínica e patológica, procedeu-se a avaliação imuno-histoquímica para pesquisa de instabilidade de microssatélites e expressão de HER2, CD44, ALDH1 e CD56. Considerando-se significativos valores de p<0,05, procedeu-se a análise de sobrevivência com recurso a curvas de Kaplan-Meier, comparação dos resultados através do teste de log-rank em análise univariada e regressão de Cox para hazards proporcionais em análise multivariada. Resultados: Com um follow-up mediano de 14±23,7 meses, constatou-se uma sobrevivência global (SG) mediana de 16±2,8 meses e uma sobrevivência livre de doença (SLD) mediana de 14±5,2 meses. Verificou-se expressão de CD44 e ALDH1, respetivamente, em 34,8% e 26,1% dos doentes. Em análise univariada, a resseção de órgãos adjacentes (p=0,010), complicações com grau de Clavien-Dindo igual ou superior a III (GCD≥III) (p=0,003), hemorragia pós-operatória de grau C (HPOGC) (p=0,030), fístula biliar (p<0,001), margens de resseção positivas (MR+) (p=0,006) e a expressão de CD44 (p=0,032) e ALDH1 (p=0,016) tiveram impacto na SG. Com impacto na SLD, verificou-se a incidência de HPOGC (p=0,042), fístula pancreática de grau C (p=0,022) e de deiscência da anastomose gastrojejunal (p=0,042). Em análise multivariada, confirmaram-se como fatores independentes com impacto na SG o GCD≥III (HR=6,64, p=0,042), as MR+ (HR=5,81, p=0,043), e a expressão de CD44 (HR=0,089, p=0,033) e ALDH1 (HR=9,24, p=0,037).Discussão: Além de confirmar o valor prognóstico de marcadores extensamente reconhecidos como tal pela literatura, o estudo demonstra o impacto das complicações pós-operatórias na SG e SLD, bem como a expressão de CD44 e ALDH1 pelo CCD e o seu impacto prognóstico, realçando o importante papel das cancer stem cells no CCD. Conclusão: O presente estudo revelou que GCD≥III, MR+ e a expressão de CD44 e ALDH1 são fatores de prognóstico independentes no CCD. Deverão, portanto, ser considerados na avaliação e estratificação prognóstica dos doentes com CCD submetidos a resseção curativa.
Introduction: Distal cholangiocarcinoma (dCCA) is one of three subtypes of cholangiocarcinoma. It has a dismal prognosis, even after curative resection, as well as a poor characterization owing to its low incidence. The present study sought to evaluate the prognostic value of clinical, pathological and immunohistochemical markers in patients diagnosed with dCCA, after surgical resection.Materials and Methods: A retrospective cohort study was conducted, with a sample of 37 patients with histological diagnosis of dCCA, after undergoing pancreaticoduodenectomy, between 2008 and 2019. The patients had an average age of 69.19 (±9.92) years, being 62.2% of them male. In conjunction with clinical and pathological assessment, immunohistochemical evaluation was carried out to examine the existence of microsatellite instability and expression of HER2, CD44, ALDH1 and CD56. Survival analysis was undertaken with Kaplan-Meier curve analysis, with the results compared with a log-rank test in univariate analysis. A proportional hazards Cox regression was also performed, for multivariate analysis.Results: After a median follow-up of 14±23.7 months, the overall survival (OS) was of 16±2.8 months and the disease free survival (DFS) was of 14±5.2 months. CD44 and ALDH1 expression was observed in 34.8% and 26.1% of the evaluated tumours, respectively. In univariate analysis, adjacent organ resection (p=0.010), a Clavien-Dindo classification ≥ III (CDC≥III) (p=0.003), grade C post-operative haemorrhage (GCPOH) (p=0.030), biliary fistula (p<0.001), positive resection margins (R+) (p=0.006), and CD44 (p=0.032) and ALDH1 (p=0.016) expression were found to influence OS. Additionally, GCPOH (p=0.042), grade C pancreatic fistula (p=0.022) and gastrojejunal fistula (p=0.042) were found to influence DFS. In multivariate analysis, CDC≥III (HR=6.64, p=0.042), R+ (HR=5.81, p=0.043) and CD44 (HR=0.089, p=0.033) and ALDH1 (HR=9.24, p=0.037) expression, were established as independent prognostic factors concerning OS.Discussion: Aside from reinstating the value of prognostic factors extensively recognised as such in literature, the study shows both the impact of post-operative morbidity in OS and DFS, as well as the expression and prognostic value of CD44 and ALDH1 in dCCA, attesting the important role of cancer stem cells in dCCA.Conclusion: The current study shows that CDC≥III, M+ and CD44 and ALDH1 expression have an important influence on OS of dCCA patients. As such, this parameters should be considered in the evaluation and prognostic stratification of patients with dCCA undergoing surgical resection.
Elena, Fiorini, Delfino Pietro, D’Agosto Sabrina, Andreani Silvia, Adamo Annalisa, Pezzini Francesco, Frusteri Cristina et al. "Unraveling the role of lymph node metastasis in PDAC and dCCA progression". Doctoral thesis, 2021. http://hdl.handle.net/11562/1045180.
Texto completoCapítulos de libros sobre el tema "Distal cholangiocarcinoma"
Yokoyama, Yukihiro, Tomoki Ebata y Masato Nagino. "Surgical Treatment of Distal Cholangiocarcinoma". En The Pancreas, 1083–88. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119188421.ch144.
Texto completoZimmermann, Arthur. "Extrahepatic Cholangiocarcinoma: Carcinoma of the Middle and Distal Common Bile Duct (Middle and Lower Bile Duct Carcinomas)". En Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 1–21. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26587-2_28-1.
Texto completoZimmermann, Arthur. "Extrahepatic Cholangiocarcinoma: Carcinoma of the Middle and Distal Common Bile Duct (Middle and Lower Bile Duct Carcinomas)". En Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 527–47. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26956-6_28.
Texto completoAbdullah Madkhali, Ahmad y Faisal Al-alem. "Distal Cholangiocarcinoma". En Bile Duct Cancer. IntechOpen, 2019. http://dx.doi.org/10.5772/intechopen.84625.
Texto completoLee, Christine U. y James F. Glockner. "Case 17.20". En Mayo Clinic Body MRI Case Review, editado por Christine U. Lee y James F. Glockner, 827–28. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199915705.003.0438.
Texto completoActas de conferencias sobre el tema "Distal cholangiocarcinoma"
Kim, Hayeon, Soo Yeon Lee, Aeree Kim, Baek-hui Kim y Chung-yeul Kim. "Abstract 3627: Comparison of genetic profiles of small and large duct type intrahepatic cholangiocarcinoma with distal extrahepatic cholangiocarcinoma". En Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3627.
Texto completoYagawa, Yohsuke, Atsushi Aruga, Nobuhiro Takeshita, Ryota Higuchi, Takehisa Yazawa, Keishi Tanigawa y Masakazu Yamamoto. "Abstract 1126: Association of CXCR4 expression with lymph node metastasis in distal cholangiocarcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1126.
Texto completoYagawa, Yohsuke, Atsushi Aruga, Nobuhiro Takeshita, Ryota Higuchi, Takehisa Yazawa, Keishi Tanigawa y Masakazu Yamamoto. "Abstract 1126: Association of CXCR4 expression with lymph node metastasis in distal cholangiocarcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1126.
Texto completoHahn, F., L. Müller, Y. Tanyildizi, D. Pinto dos Santos, C. Düber, PR Galle, A. Weinmann, R. Kloeckner y A. Mähringer-Kunz. "Distant metastases in patients with intrahepatic cholangiocarcinoma: Does location matter?" En 36. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402230.
Texto completoSavino, M. S., L. Cavinato, G. Costa, F. Fiz, G. Torzilli, L. Vigano y F. Ieva. "Distant supervision for imaging-based cancer sub-typing in Intrahepatic Cholangiocarcinoma". En 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2022. http://dx.doi.org/10.1109/embc48229.2022.9871262.
Texto completo